tiprankstipranks
Advertisement
Advertisement

UPB Stock Latest News

3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
Market News3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
7d ago
UPB
AIOT
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
PremiumRatings
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
9d ago
UPB
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
PremiumCompany Announcements
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
20d ago
UPB
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
PremiumThe Fly
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
20d ago
U
CG
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
20d ago
TW
AGX
Upstream Bio downgraded to In Line from Outperform at Evercore ISI
PremiumThe FlyUpstream Bio downgraded to In Line from Outperform at Evercore ISI
21d ago
UPB
Upstream Bio Launches $150 Million At-The-Market Program
Premium
Company Announcements
Upstream Bio Launches $150 Million At-The-Market Program
21d ago
8K
UPB
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
Premium
Ratings
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
21d ago
UPB
Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster
PremiumRatings
Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster
21d ago
UPB
Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug
PremiumRatings
Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug
21d ago
UPB
Is UPB a Buy, Before Earnings?
PremiumPre-Earnings
Is UPB a Buy, Before Earnings?
1M ago
UPB
Buy Rating on UPB Driven by Robust Verekitug Phase 2 Data and Upcoming Phase 3 Catalysts in CRSwNP and Severe Asthma
PremiumRatings
Buy Rating on UPB Driven by Robust Verekitug Phase 2 Data and Upcoming Phase 3 Catalysts in CRSwNP and Severe Asthma
1M ago
UPB
3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026
PremiumMarket News3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026
2M ago
UPB
VERA
Upstream Bio announces verekitug met the primary endpoint
Premium
The Fly
Upstream Bio announces verekitug met the primary endpoint
2M ago
UPB
XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026?
Premium
Market News
XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026?
2M ago
IBB
UPB
Midday Fly By: January payrolls jump, Ford reports mixed Q4
PremiumThe Fly
Midday Fly By: January payrolls jump, Ford reports mixed Q4
2M ago
F
PM
Buy Rating on UPB Driven by Tezspire‑Comparable Efficacy, Convenient Q12W Dosing, and Solid Cash Runway Supporting Verekitug’s Long‑Term Potential
PremiumRatings
Buy Rating on UPB Driven by Tezspire‑Comparable Efficacy, Convenient Q12W Dosing, and Solid Cash Runway Supporting Verekitug’s Long‑Term Potential
2M ago
UPB
Upstream Bio Reports Positive Phase 2 Verekitug Asthma Results
PremiumCompany Announcements
Upstream Bio Reports Positive Phase 2 Verekitug Asthma Results
2M ago
8K
UPB
Upstream Bio Reports Positive Phase 2 Severe Asthma Data
PremiumCompany Announcements
Upstream Bio Reports Positive Phase 2 Severe Asthma Data
2M ago
8K
UPB
Upstream Bio reports results from Phase 2 VALIANT clinical trial
PremiumThe FlyUpstream Bio reports results from Phase 2 VALIANT clinical trial
2M ago
UPB
Upstream Bio management to meet virtually with Piper Sandler
Premium
The Fly
Upstream Bio management to meet virtually with Piper Sandler
3M ago
UPB
Positioning Upstream Bio for Commercial Success: Buy Rating on UPB Driven by Physician Enthusiasm and Long-Acting TSLP Opportunity Ahead of VALINAT Readout
Premium
Ratings
Positioning Upstream Bio for Commercial Success: Buy Rating on UPB Driven by Physician Enthusiasm and Long-Acting TSLP Opportunity Ahead of VALINAT Readout
3M ago
UPB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >